20530 ⎘
Medicinal preparations containing organic active ingredients; Carbohydrates; Sugars; Derivatives thereof Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
USE OF STING AGONIST AS CANCER TREATMENT
#302Cyclic dinucleotides useful for the treatment of inter alia cancer
#303Aqueous ophthalmic solution
#304COMBINED USE OF A CHEMOTHERAPEUTIC AGENT AND A CYCLIC DINUCLEOTIDE FOR CANCER TREATMENT
#305Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
#306Compositions and methods for reducing blood alcohol content
#307TH1-inducing adjuvant comprising combination of different nucleic acid adjuvants, and use of same
#308Branched oligonucleotides
#309Use of NADH or salt thereof in preparation of drugs or health-care products for treating phenylketonuria
#310Compositions and methods for treating viral infections
#311Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
#312Compositions including beta-glucans and method of use
#313NAD+ COENZYME FORMULATION AND METHODS OF MAKING AND USING THE SAME
#314LIPOSOMAL APPARATUS AND MANUFACTURING METHODS
#315Compounds
#316Compositions and methods for inhibiting “stimulator of interferon gene”-dependent signalling
#317Application of cyclic dinucleotide (cGAMP) in anti-tumor field
#318Treating Arrhythmia with Mitochondrial-Targeted Antioxidants
#319Methods and assays for treating hantavirus infections
#320SOPHOROLIPID ESTER CHAIN LENGTH DEPENDENCE ON THE INHIBITION OF HUMAN PATHOGENS
#321METHOD AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY DISORDERS
#322Methods and compositions for treating phenylketonuria
#323USE OF NADH OR SALT THEREOF IN PREPARATION OF DRUGS OR HEALTH-CARE PRODUCTS FOR TREATING PHENYLKETONURIA
#324Association of a tetrapeptide and a glyceryl ester for treating androgenic alopecia
#325USE OF NADH AND NMN IN PREPARATION OF DRUGS OR HEALTH-CARE PRODUCTS FOR TREATING PARKINSON'S DISEASE
#326Cyclic di-nucleotide compounds as sting agonists
#327Oligonucleotide analogues incorporating 5-aza-cytosine therein
#328METHODS USEFUL IN THE PREVENTION OF HYPOXIC INJURY
#329Ophthalmic solution comprising diquafosol
#330Lyophilized pharmaceutical compositions
#331COMPOSITIONS
#332Cyclic dinucleotides for cytokine induction
#333COMPOSITIONS
#334Drug formulations
#335Anti-tumor therapy
#336METHODS AND COMPOSITIONS FOR INHIBITION OF EGF/EGFR PATHWAY IN COMBINATION WITH TYROSINE KINASE INHIBITORS
#337Compositions and methods for treating melanoma
#338COMPOSITION CONTAINING MODIFIED DERIVATIVES OF A CYTIDINE ANTIMETABOLITE FOR THE TREATMENT OF SUSCEPTIBLE DISEASE
#339Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
#340USE OF STING AGONIST AS CANCER TREATMENT
#341Alkynyl-derivatized cap analogs, preparation and uses thereof
#342SENESCENCE AND SENESCENCE ASSOCIATED SECRETORY PHENOTYPE
#343Inhibitors of CACNA1A/ALPHA1A subunit internal ribosomal entry site (IRES) and methods of treating spinocerebellar ataxia type 6
#344STING crystals and modulators
#345METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES
#346Methods for the production of collagen IV
#347Composition for the management of nausea and vomiting
#348Pharmaceutical Compositions Comprising a GPG Oligodeoxynucleotide and Cyclic Di-GMP
#349Oligonucleotide analogues incorporating 5-aza-cytosine therein
#350Immunostimulatory combinations
#351COMPOSITIONS AND METHODS FOR REDUCING BLOOD ALCOHOL CONTENT
#352METHODS FOR TREATING IMMUNE DISEASES
#353Nucleotide and oligonucleotide prodrugs
#354Particulate pharmaceutical composition
#355Compositions and methods for treating viral infections
#356Epitope of RSV fusion protein and antibody recognizing the same
#357DRUG COMBINATIONS
#358Short oligonucleotides as vaccine adjuvants and therapeutic agents
#359Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
#360COMPOSITION FOR TREATMENT OF NEURODEGENERATIVE DISEASE
#361Solid oral compositions based on S-adenosyl methionine and/or NADH and process for obtaining them
#362Topical Formulation to Enhance Genital Sensation and Function
#363Alkynyl-derivatized cap analogs, preparation and uses thereof
#364Protective Supplement Configuration
#365Bacterial ribonucleic acid cell wall compositions and methods of making and using them
#366COMPOSITIONS COMPRISING HYALURONIC ACID AND DERMATAN SULPHATE FOR THE TREATMENT OF BEING OVERWEIGHT AND OBESITY
#367COMPOSITION FOR TREATING A CIRCADIAN RHYTHM DISORDER
#368Charge conversional ternary polyplex
#369DINUCELOSIDE POLYPHOSPHATES FOR THE TREATMENT OF PAIN
#370Ophthalmic solution comprising diquafosol
#371Compositions and methods for activating stimulator of interferon gene-dependent signalling
#372Methods of treating necrotizing enterocolitis by administering nuclear oligomerization domain-2 agonists,TLR9 agonists and TLR4 antagonists
#373Product and process for liquefaction of mucus or sputum
#374Methods and compositions for treating neuropathies
#375Tolterodine-containing adhesive patch
#376Compositions and methods for cancer immunotherapy
#377Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
#378METHOD FOR THE TREATMENT OF PULMONARY DISEASE AND METHOD OF PRODUCING PROTEINS OF USE THEREIN
#379NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS
#380Compositions including β-glucans and methods of use
#381Drug formulations
#382Lipid compositions for nucleic acid delivery
#383INHIBITOR FOR CORNEAL EPITHELIAL CELL DEATH, INHIBITOR CHARACTERIZED BY COMBINING HYALURONIC ACID AND FLAVIN ADENINE DINUCLEOTIDE
#384OPHTHALMIC SOLUTION COMPRISING DIQUAFOSOL, METHOD FOR PRODUCING THE SAME, AND METHOD FOR INHIBITING FORMATION OF INSOLUBLE PRECIPITATE
#385Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
#386DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION
#387Compositions and methods for reducing blood alcohol content
#388Liposomal apparatus and manufacturing methods
#389Oligonucleotide analogues incorporating 5-aza-cytosine therein
#390Compositions and methods for treating viral infections
#391Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
#392Pharmaceutical or cosmetic composition containing nicotinic acid adenine dinucleotide phosphate or derivative thereof
#393Immunotherapy comprising TLR9 ligand and CD40 ligand
#394Reporter system for high throughput screening of compounds and uses thereof
#395Uses of Beta-Nicotinamide Adenine Dinucleotide
#396Method for ameliorating or preventing arrhythmic risk associated with cardiomyopathy by improving conduction velocity
#397Method for ameliorating or preventing arrhythmic risk associated with cardiomyopathy
#398HUMAN FERTILITY TEST USING DPY19L2
#399Nucleotide and oligonucleotide prodrugs
#400RNAi-Mediated Inhibition of RHO Kinase for Treatment of Ocular Disorders
#401Method for the treatment of pulmonary disease and method of producing proteins of use therein
#402Use of toll-like receptor-9 agonists
#403Particulate pharmaceutical composition
#404Oligonucleotide analogs as therapeutic agents
#405Anticancer drug comprising inhibitor of TMPRSS4
#406Complex and method for enhancing nuclear delivery
#407Modulation of sodium channels by nicotinamide adenine dinucleotide
#408IMMUNOSTIMULATORY COMBINATIONS
#409RNAi-mediated inhibition of Rho kinase for treatment of ocular disorders
#410Method for protecting and treating at least one muscarinic receptor from dysfunction resulting from free radical damage
#411Liposomal apparatus and manufacturing method
#412Compositions and methods for treating viral infections
#413Method for modulating or controlling sodium channel current by reactive oxygen species (ROS) originating from mitochondria
#414TOLL-LIKE RECEPTOR 9 AGONISTS FOR THE TREATMENT OF ANXIETY-RELATED DISORDERS AND INFLAMMATORY DISORDERS
#415Methods of Affecting Biological Function Through Circadian Clock Feedback Cycle by NAMPT-Mediated NAD+ Biosynthesis
#416Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
#417Function of GPR4 in vascular inflammatory response to acidosis and related methods
#418CHARGE CONVERSIONAL TERNARY POLYPLEX
#419P2Yreceptor agonists for treating lung diseases
#420L-citrulline for treating endothelial dysfunction and erectile dysfunction
#421NOVEL LIPOPHILIC COMPOSITIONS AND USES THEREOF
#422Ex vivo uses of immunostimulatory combinations
#423Method of increasing tear production with purinergic receptor agonists
#424Methods and compositions for treating neuropathies
#425Oligonucleotide analogues incorporating 5-aza-cytosine therein
#426METHODS AND IMMUNE MODULATOR NUCLEIC ACID COMPOSITIONS FOR PREVENTING AND TREATING DISEASE
#427METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES
#428PRODUCT AND PROCESS FOR LIQUEFACTION OF MUCUS OR SPUTUM
#429P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis
#430Modulation of the P2Y2 Receptor Pathway
#431NOVEL MEMORY CTL INDUCTION POTENTIATOR
#432RNAi-Mediated Inhibition of RHO Kinase for Treatment of Ocular Disorders
#433PQS and its conjugates as adjuvants and their uses in pharmaceutical compositions
#434TLR9 agonist and CD40 agonist immunostimulatory combinations
#435SOLID ORAL COMPOSITIONS BASED ON S-ADENOSYL METHIONINE AND/OR NADH AND PROCESS FOR OBTAINING THEM
#436METHODS OF REDUCING CELL DEATH FOLLOWING HYPOXIA / REOXYGENATION
#437Modulation of sodium channels by nicotinamide adenine dinucleotide
#438METHOD OF IMPROVING STORAGE STABILITY OF SUBSTANCE
#439Uses of Dinucleotide Polyphosphate Derivatives
#440METHODS AND FORMULATIONS FOR PROTECTING CELLS, AND FOR TREATING DISEASES AND CONDITIONS BY OPTIMIZING THE INTRACELLULAR CONCENTRATION OF NAD
#441Drug-eluting stents coated with P2Yreceptor antagonist compound
#442Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
#443Anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use
#444Product and process for liquefaction of mucus or sputum
#445Method of treating dry eye disease with purinergic receptor agonists
#446Use of Del-1 in hair, bone and cartilage regeneration
#447Method for attentuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
#448P-(2′-deoxycytidine 5′-)P-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating cystic fibrosis
#449Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof
#450RNAi-mediated inhibition of RHO kinase for treatment of ocular disorders
#451Nucleotide and oligonucleotide prodrugs
#452Processes for regulating blood glucose in a mammal
#453Oligonucleotide analogues incorporating 5-aza-cytosine therein
#454In Vivo Enhancement of Immune System Recognition of Neoplasms Following Treatment with an Oncolytic Virus or Gene Therapy Vector
#455P2Y6 receptor agonists for treating lung diseases
#456High solubility composition with high isoflavone concentration and process of producing same
#457Anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use
#458Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases
#459Compositions and methods for treating viral infections
#460Diagnostic and therapeutic agents for rheumatoid arthritis
#461Drug-eluting stents coated with P2Yreceptor antagonist compound
#462Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes
#463Method for stimulating the immune, inflammatory or neuroprotective response
#464Methods and compositions for increasing the efficacy of an agent that directly or indirectly affects a muscarinic receptor through administration of a pyrophosphate analog
#465Methods and compositions for protecting and treating muscarinic receptors by administering a pyrophosphate analog to a subject exposed to bacterial, fungal, viral, prion or algal infection
#466Corneal epithelial migration promoter
#467Methods and compositions for protecting and treating muscarinic receptors through administration of at least one protective agent
#468Methods and compositions for protecting or treating muscarinic receptors through administration of pyrophosphate analog in subjects exposed to toxic or carcinogenic metals or metal ions
#469Methods and compositions for treating neuropathies
#470Nucleotide based medicament and method of use for treatment of conditions in humans
#471Methods and compositions for protecting and treating at least one muscarinic receptor from dysfunction not resulting from oxidative stress, toxic actions of metals or infectious agents by administering a pyrophosphate analog
#472Mucolytic and anti-elastase compounds and methods of use thereof
#473Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
#474Method of enhancing drainage of lacrimal system with purinergic receptor agonists
#475Compositions for the treatment of glaucoma or ocular hypertension
#476Method of stabilizing reduced nicotinamide adenine dinucleotide or reduced nicotinamide adenine dinucleotide phosphate
#477Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
#478Single dose fast dissolving azithromycin
#479Nutraceutical compositions to up-regulate SIRT1 and methods of use
#480Nucleoside derivatives and methods of use thereof
#481Pharmaceutical composition Mix A to treat health conditions associated with elevated glucose levels
#482Pharmaceutical composition Mix B to treat health conditions associated with elevated glucose levels
#483Active ingredient complexes, compositions and methods for hangover relief and to ameliorate alcohol-induced liver damage
#484Methods of ameliorating the effects of alcoholic liver damage
#485COVID-19 treatment and methods
#486Supramolecular systems based on dynamic self-organizing nanostructures with antiviral properties
#487Method and compositions for treating chronic inflammatory disorders